Market Overview

ACADIA Pharma Shares Move Higher as JMP Boosted Price Target from $16 to $27

Share:
Related ACAD
Minerva On Track to Initiate Phase III Schizophrenia Study
Wall Street's M&A Chatter From June 21: Staples-Sycamore Partners, Diageo-Casamigos, Bristol-Myers, Acadia Pharma

JMP Securities maintains ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) with a Market Outperform and raises the price target from $16.00 to $27.00.

The stock has opened up more than 4 percent higher. With the stock last trading at $19.45, the firm's new price target implies potential upside of about 39 percent.

Latest Ratings for ACAD

DateFirmActionFromTo
Feb 2017Ladenburg ThalmannAssumesBuyBuy
Nov 2016Goldman SachsInitiates Coverage OnNeutral
Nov 2016Bank of AmericaUpgradesNeutralBuy

View More Analyst Ratings for ACAD
View the Latest Analyst Ratings

Posted-In: News Price Target Analyst Ratings

 

Related Articles (ACAD)

View Comments and Join the Discussion!